Q-omics provides the consensus-scored MAP2K1P1 profile across patient tissues and cancer cell-line models. MAP2K1P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MAP2K1P1 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, MAP2K1P1 RNA expression shows 10,580 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight MESO, COAD, and DLBC as cancer lineages where MAP2K1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP2K1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP2K1P1 survival associations across molecular data types. MAP2K1P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP2K1P1 RNA expression–survival associations across cancer types. High MAP2K1P1 expression shows unfavorable associations in MESO, KICH, DLBC, CESC and CHOL, but favorable associations in LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MAP2K1P1 RNA expression.
This table summarizes MAP2K1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MAP2K1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP2K1P1 shows higher tumor expression in COAD, STAD, HNSC, PRAD and KIRC. The COAD box plot shows higher MAP2K1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.199, t-test p < 0.001).
This table shows molecular features associated with MAP2K1P1 in patient tissues and cancer cell lines. In patient samples, MAP2K1P1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
